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Iron is essential for normal neuronal functioning [1], but 
in excess, labile reactive iron enhances free radical 
induced cell death [2]. Thus, cellular iron homeostasis is 
tightly regulated, including sequestration in a 
bioavailable and non-toxic form by ferritin, the major 
cellular iron storage protein [3]. However, iron does 
accumulate with aging (see below) and iron 
dysregulation (and accumulation) has been implicated 
in the pathogenesis of various CNS disorders including 
Alzheimer’s Disease (AD) [4] and Parkinson’s Disease 
(PD) [5], highlighting the key role of iron homeostasis 




The seminal human post-mortem study by Hallgren and 
Sourander (1958) showed iron accumulation within the 
globus pallidus (GP), striatum (STR, including both 
caudate and putamen), thalamus and various cortical 
regions [6]. Subsequent investigations have shown 
similar findings, with the basal ganglia exhibiting the 
greatest levels of iron accumulation [7]. Iron in the GP 
greatly increases during development, but plateaus in 
early adulthood, with continual iron accumulation in the 
STR into senescence (biological aging) [8]. Iron has 
also been shown to accumulate with aging in the 
substantia nigra (SN) [8]. 




















Despite  regulation,  brain  iron  increases  with  aging  and  may  enhance  aging  processes  including
neuroinflammation.  Increases  in magnetic  resonance  imaging  transverse  relaxation  rates, R2 and R2*,  in  the
brain  have  been  observed  during  aging.  We  show  R2  and  R2*  correlate  well  with  iron  content  via  direct
correlation  to  semi‐quantitative  synchrotron‐based X‐ray  fluorescence  iron mapping, with  age‐associated R2
and R2*  increases  reflecting  iron  accumulation.    Iron  accumulation was  concomitant with  increased  ferritin
immunoreactivity  in basal ganglia regions except  in the substantia nigra  (SN). The unexpected dissociation of
iron  accumulation  from  ferritin‐upregulation  in  the  SN  suggests  iron  dyshomeostasis  in  the  SN.    Occurring
alongside microgliosis and astrogliosis, iron dyshomeotasis may contribute to the particular vulnerability of the
SN.   Dietary restriction (DR) has long been touted to ameliorate brain aging and we show DR attenuated age‐
related  in  vivo R2  increases  in  the  SN over  ages 7 – 19 months,  concomitant with normal  iron‐induction of
ferritin expression and decreased microgliosis. Iron is known to induce microgliosis and conversely, microgliosis
can  induce  iron  accumulation, which  of  these may  be  the  initial  pathological  aging  event warrants  further
investigation. We  suggest  iron  chelation  therapies  and  anti‐inflammatory  treatments may be putative  ‘anti‐
brain aging’ therapies and combining these strategies may be synergistic. 
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The apparent iron dyshomeostasis during aging may 
predispose the brain to neurodegenerative disease.  
Indeed, the role of iron in enhancing reactive oxygen 
species (ROS) and mitochondrial injury is key to the 
“mitochondrial theory of aging” [9].  Cellular 
production of ROS is unavoidable with ROS substrates 
being by-products of normal mitochondria respiration.  
The brain is particularly susceptible to oxidative stress 
due to its high oxygen consumption; high content of 
peroxidizable unsaturated fatty acids; high amounts of 
pro-oxidants (iron and ascorbate); and poor antioxidant 
defenses [10].  Further, the high numbers of do-
paminergic neurons in the SN are known to be 
continuously metabolically active and particularly prone 
to oxidative stress [11]. This increased metabolic 
burden has been suggested to accelerate the aging of SN 
neurons; indeed, death of dopaminergic neurons occurs 
at a 5-10% greater rate than any other neuronal type 
[12]. This innate predisposition of the SN to oxidative 
damage makes it particularly susceptible to deleterious 
iron accumulation and thus, a potential therapeutic 
target. Indeed, oxidative damage is very much a feature 
of neurodegenerative diseases and may partly explain 
why advancing age is a major risk factor. In C. elegans, 
aging is also associated with iron accumulation and 
increased dietary levels of iron were shown to weaken 
protein homeostasis so as to accelerate age-related 
protein aggregation, a feature of aging [13].   
 
Magnetic resonance imaging (MRI) is a non-invasive 
modality that has been used to elucidate morphological 
changes with aging, demonstrating decreases in cortical 
and striatal brain volumes [14]. More recently, other 
MRI techniques including relaxometry have provided 
indirect evaluation of age-related changes in brain iron 
[15]. These methods depend on iron-induced 
enhancement of longitudinal (T1) and transverse (T2) 
relaxation of neighboring protons - predominantly 
affecting the latter. However, iron also induces local 
magnetic field inhomogeneities and increases 
susceptibility, shortening T2* relaxation times [16, 17]. 
It should be noted that the T2 measurements are also 
affected by diffusion of the spins during the interecho 
time for an applied spin-echo sequence [18]. The 
reciprocal of T1, T2 and T2* relaxation times are the 
relaxation rates, R1, R2 and R2*, respectively, thought 
to correlate better with iron than the former [19]. MRI 
has demonstrated age-related decreases of T2 and T2* 
(increased R2 and R2*, respectively), primarily in the 
basal ganglia, in both man and rhesus monkey [17, 20-
23]. Higher R2 and R2* were observed in the STR, with 
a greater increase in the GP [22, 24], and consistent 
with iron accumulation in these regions (see above). 
Age-related alterations in relaxation times/rates have 
also been shown to predict age-related impaired motor 
function [21, 25] and cognitive dysfunction [26].  
Ever since McKay et al. (1935) [27] evoked life 
extension in rats by restricting food intake, dietary 
restriction (DR) has been studied in various rodent and 
primate models of aging. DR is defined as reduction of 
a particular or total nutrient intake without causing 
malnutrition by reducing total food intake or inter-
mittent fasting. Focused on the health-span effects of 
DR, i.e. time spent free of age-related illness, studies 
showed DR-amelioration of age-associated morbidities 
[28]. This is undoubtedly due to a multitude of cellular 
alterations stimulated by DR, such as attenuation of 
oxidative damage [29], including protein oxidation (33), 
and suppression of glycolysis [29]. DR also reduces 
expression of genes encoding proteins involved in the 
innate immune response and its oxidative capacity [30]. 
Attenuation of such cellular changes in aging may 
underlie the positive impact of DR, with cognitive and 
motor functions as beneficiaries of DR at the functional 
level [31].  The extension of health-span by DR may 
also be mediated by down-regulation of the mammalian 
molecular target of rapamycin (mTOR), since impaired 
mTOR has similar effects as DR, including lifespan 
extension [32, 33]. DR has also been known to reduce 
iron accumulation [34, 35], but only one study has 
demonstrated DR-amelioration of age-related T2 
increases in the basal ganglia, combined with improved 
motor function [16]. Furthermore, iron chelation was 
shown to extend healthspan and lifespan in C. elegans 
[13].  DR also induces hormesis, acting as a mild 
stressor, enhancing host defense mechanisms to natural 
stressors encountered during life [29].  The glial 
activation, in the absence of neurodegeneration, 
observed in the aging brain, has also been shown to be 
attenuated by DR [36]. 
 
In this study, we tested the hypothesis that iron changes 
underlie the age-related alterations in MR relaxation 
rates in the basal ganglia and that relaxation rates 
provide proxy measures of iron content and/or 
biological brain age (study 1). R1, R2 and R2* indices 
in the basal ganglia of aging C57BL/6J mice were 
correlated with synchrotron radiation X-ray fluo-
rescence (SRXRF) elemental iron maps, with ferritin 
immunohistochemistry performed to assess iron 
dyshomeostasis. Typically,  R1, R2 and R2* have been 
correlated against previously published post-mortem, 
generally qualitative, histochemical Perl’s staining for 
iron content [6]; or from bulk analysis of tissue samples 
[37]. By using SRXRF in our study, we obtained semi-
quantitative spatial iron measures from the same brain 
region/tissue that relaxometry was also performed on. In 
addition, age-associated neuroinflammation was 
assessed with glial fibrillary acidic protein (GFAP) and 
ionized calcium binding adaptor molecule (iba1) 
immunohistochemistry, staining for astrocytes and 
microglia, respectively. 
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The effectiveness of MRI measure(s) to assess 
biological brain age was tested in a model of delayed 
brain aging stimulated by DR (study 2) and focused 
specifically in the SN, a brain area particularly vulnerable 
to disease [11]. DR attenuated the age-associated changes 
in MRI (study 1) as well as restored iron homeostasis and 




In study 1, age-related (over 2 – 27 months) changes in 
relaxation rates, striatal volumes, iron, and ferritin, ba1 
and GFAP IHC were investigated, whereas in study 2, 
we studied the effects of DR on these measurements. 
 
Study 1:  Ex vivo characterization of the normally 
aging mouse brain 
 
Age-related alterations in MR Relaxation Rates  
 
Typical R1, R2 and R2* maps of the brain including the 
substantia nigra at approximate Bregma -3.28 are shown 
in Fig. 1. 
 
R1 relaxation rate:  R1 was significantly different in 
the STR, GP and SN (P < 0.01, < 0.0001 and < 0.0001, 
respectively; Fig. 2A – C; Supplemental Table 1). Post-
hoc testing showed that R1 was higher in 27 than 2-
month-old mice in the STR (9%; P < 0.01; Fig. 2A). In 
the GP, R1 was higher at 6, 13, 19 and 27 compared to 
2 months (8, 8, 12 and 17%; P < 0.05, 0.01, 0.001 and 
























old mice compared to those at 6 and 13 months (8%; P 
< 0.01 and 0.01, respectively; Fig. 2B). Much of the R1 
increase occurred over 2 – 6 months of age in the SN 
with R1 higher at all ages compared to 2 month old 
mice (6, 13, 19 and 27 months; 7, 7, 10 and 11%; P < 
0.05, 0.05, 0.001 and 0.001, respectively; Fig. 2C).  
 
R2 relaxation rate: A pronounced effect of age on R2 
was observed in the STR, GP and SN (P < 0.0001; Fig. 
2D – F; Supplemental Table 1). In the STR, R2 was 
higher at 6, 19 and 27 months compared to at 2 months 
(6, 9 and 10%, respectively; P < 0.001; Fig. 2D), but a 
progressive increase in R2 was not observed, as R2 at 
13 months was lower than at 6 months (3%; P < 0.05), 
although still higher than that at 2 months (9%; P < 
0.001). Much of the increase in R2 was observed 
between 13, and 19 and 27 months with R2 being 
comparable at 19 and 27 months of age.  
 
R2 was higher at 6, 13, 19 and 27 compared to 2 months 
in the GP (9, 9, 21 and 20%; P < 0.001, for all; Fig. 2E) 
with R2 being similar at aged 6 and 13, and 19 and 27 
months. Much of the increase in R2 during aging 
occurred between 2 - 6 months and 13 - 19 months (9 
and 10%, respectively; P < 0.001). The changes in R2 
in the SN were similar to that observed in the GP, with 
R2 higher in 6, 13, 19 and 27 months compared to 2 
months (16, 15, 25 and 27%; P < 0.01, 0.01, 0.001 and 
0.001, respectively; Fig. 2F). Furthermore, much of the 
increase in SN R2 occurred between 2 – 6, with R2 










































































R2* relaxation rate: R2* appeared to increase from 6 
– 19 months in the GP and SN (Fig. 3D and F), with 
more modest changes in the STR (Fig. 3B). Indeed, R2* 
significantly differed with aging in the STR, GP and SN 
(P < 0.0001, 0.0001 and 0.0001, respectively; 
Supplemental Table 1).  
 
In the STR, R2* was higher at 13, 19 and 27 compared 
to 2 months (10, 16 and 27%, respectively; P < 0.001, 
Fig. 2G). R2* also increased between 13 and 19 months 
(6%; P < 0.05), and 19 and 27 months (9%; P < 0.001). 













































higher at 13, 19 and 27 months compared to 6 (20, 40 
and 56%; P < 0.001) and R2* higher at 19 months 
compared to 13 (16%; P < 0.001), and 27 months higher 
than that at 19 (12%; P < 0.001, Fig. 2H).  
 
R2* was higher at all ages compared to 2 months in the 
SN (6, 13, 19 and 27 months; 26, 31, 50 and 57%, 
respectively; P < 0.001; Fig. 2I).  R2* at aged 13 months 
was lower than that at 19 and 27 months (14 and 19% P 
< 0.05 and 0.001, respectively). The significant R2* 
increases over 19 and 27 months observed in both the 
STR and GP was not observed in the SN.  
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Age-related changes in SRXRF-measured brain iron 
 
Increased R2* clearly aligned with areas of increased 
iron in the SRXRF iron maps (Fig. 3A - F). Iron 
increased with age in the STR, GP and SN (P < 0.0001; 
Supplemental Table 1). In the STR, iron levels were 
similar at 2 and 6 months, but higher at 19 (82 and 52%; 
P < 0.001 and 0.01, respectively; Fig. 3G) and 27 
months (91 and 59%; P < 0.01, respectively; Fig. 3G). 
The GP also had higher iron levels at 19 (210 and 
160%; P < 0.001 and 0.001; Fig. 3H) and 27 months 
(307 and 242%; P < 0.001 and 0.001; Fig. 3H) than at 2 
and 6 months, respectively. Similar findings were also 
observed in the SN, where levels of iron were 
comparable at 2 and 6 months, but higher at 19 (201%; 
P < 0.5; Fig. 3I) compared to 2 months and at 27 
months (235 and 125%; P < 0.01 and 0.5; Fig. 3I) 
compared to 2 and 6 months, respectively.  Whilst iron 
levels were similar at 19 and 27 months, only the latter 





































Correlation of individual relaxation rates with SRXRF 
measured iron 
 
Relaxation rates were correlated with SRXRF iron 
measurements from all three basal ganglia regions rather 
than individual regions to provide a wide range of iron 
concentrations for correlations. R1, R2 and R2* 
significantly positively correlated with iron content in the 
three basal ganglia regions, STR, GP and SN (r2 = 
0.5219, 0.6172 and 0.8256, respectively; all correlations, 
P < 0.001; Fig. 4A-C). Nonlinear regression analysis 
suggests that for R1 and R2 in particular, there may be a 
saturation effect as at high iron levels, R1 and R2 appears 
to plateau. However, overall R2* correlated better with 
iron than R1 (P < 0.05) and were similar to R2.   
 
Changes in striatal volume with aging 
  
STR volumes normalized to whole brain volumes were 
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1) but lower at 13, 19 and 27 months compared to at 2 
months (P < 0.001; Supplemental Fig. 1). STR volume 
at age 27 months was also lower than that at 6 month 
(7%, P < 0.05). 
 
Age-related changes in ferritin-immunopositive cell 
numbers 
 
Numbers of ferritin-immunopositive cells differed in the 
STR (P < 0.0001), GP (P < 0.0001) and SN (P < 0.01; 
Fig. 5A-C; Supplemental Table 1) with aging. More 
ferritin-immunopositive cells were observed at 6 (33%), 
19 (67%) and 27 months (67%) compared to 2 months 
(P < 0.05, 0.001 and 0.001, respectively) in the STR 
(Fig. 5A). Ferritin-expressing cells were also elevated 
between 6 and 27 months (25%; P < 0.05), but similar 








































In the GP, numbers of ferritin-immunopositive cells 
were similar at 2 and 6 months, but higher at 19 and 27 
months (by 80 and 100% compared to 2 months, P < 
0.001; 50 and 67% compared to 6 months, P < 0.001; 
Fig. 5B). Numbers of ferritin-expressing cells in the SN 
were also similar at 2 and 6 months (Fig. 5C). However, 
less ferritin-immunopositive cells were detected at 19 
and 27 months compared to those at 6 months (20 and 
33%; P < 0.01 and < 0.05, respectively). 
 
Neuroinflammation during aging 
 
GFAP-immunohistochemistry: The number of GFAP-
positive cells was significantly different between the 
ages in the STR, GP and SN (P < 0.0001, < 0.01, < 
0.05, respectively; Fig. 6A-C; Supplemental Table 1). 
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and 6 months in the STR, with 27 month mice exhibiting 
higher numbers of astrocytes than 2 (529%), 6 (292%) 
and 19 months old (78%) (compared with 2 and 6 
months, P < 0.001; compared with 19 months P < 0.05). 
19 month mice also expressed higher levels of GFAP 
than 2 month-old mice (253%; P < 0.05) (Fig. 6A). Little 
change was observed in GFAP-positive cells in the GP 
between 2, 6 and 19 months, but 27 month mice had 
higher levels than 2 month-old mice (94%; P < 0.05). 
 
In the SN, comparable levels of GFAP were observed 
from 2 - 6 and 19 - 27 months, with 19 and 27 months 
expressing higher levels of GFAP than 6 months (35 
and 30%, P < 0.01 and 0.05, respectively; Fig. 6C).  
 
Iba1 immunohistochemistry: Iba1 immunopositive 
cell counts were significantly altered with aging in the 
STR, SN and GP (P < 0.05, 0.01 and 0.01 respectively; 
Fig 7A-C; Supplemental Table 1). Post-hoc testing 
showed that Iba1 cells were significantly higher at 27 
months compared to 2 months in both the STR (Fig. 
7A) and GP (Fig. 7B) (P < 0.05; 36 and 25%  respective-


































cells were higher at 27 months than at 6 months (P < 
0.01, 39 and 36% respectively). Iba1 positive cells were 
unchanged between 2 and 6 and 19 - 27 months in all 3 
studied basal ganglia regions (Fig. 7A-C). 
 
Study 2:  Dietary restriction (DR)-induced 
attenuation of age-related brain changes in the SN  
 
Effect of DR on in vivo R2 and ferritin 
immunoreactivity 
 
In vivo R2: Aging led to an increase in in vivo R2 in the 
SN, similar to that observed in study 1 (P < 0.0001; Fig. 
8A). A significant effect of DR (P < 0.001) was also 
observed, as well as an interaction between age and 
feeding regimen (P < 0.01). DR and ad libitum (AL) 
mice both showed similar decreases in R2 at ages 7 and 9 
months, with little change to 12 months (Fig. 8A). After 
12 months of age, R2 in AL mice increases with little 
change in DR mice (Fig. 8A). Multiple comparison 
testing showed progressive disparity between AL and DR 
groups at aged 15 and 19 months (3 and 4%, respec-





































Figure 7.  Iba1  cell  count  increases with  age  in  the  (A)  striatum  (B)  globus  pallidus  and  (C)  substantia  nigra  at  different  ages.
Significance level at *, P < 0.05, compared to 2 month and ##, P < 0.01, compared to 6 month, respectively. 
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Ferritin immunohistochemistry: Ferritin-immuno-
positive cell numbers in the SN decreased with aging as 
in study 1 (P < 0.001) and multiple comparisons testing 
showed the reduction in cell numbers was only 
significant in the AL and not DR mice (27% and 18%, 
respectively; P < 0.01; Fig. 8B-D). An effect of feeding 
regimen or an interaction between feeding regimen and 
age was not observed.  
 
Effect of dietary restriction on neuroinflammation 
 
GFAP Immunohistochemistry: Numbers of GFAP 
immunopositive cells were significantly altered with 
age in the SN (P < 0.001). No effect of DR or an 
interaction between DR and age was observed in the 
SN. Multiple comparisons testing revealed numbers of 
GFAP-positive cells were increased in both AL and DR 
mice at 19 compared to 7 months (36% and 38%, P < 
0.01 and 0.001; Fig. 9A-C). 
 




































showed a significant effect of age in the SN (P < 
0.0001). There was also a significant effect of DR (P < 
0.05) and an interaction between age and DR (P < 
0.05). Iba1 cell numbers were elevated in both AL 
(25%, P < 0.001) and DR mice (12%, P < 0.01; Fig. 
10A) with post-hoc multiple comparisons tests 
revealing significantly lower numbers of Iba1 positive 
cells in DR compared to AL mice at 19 months (10%, P 




This is the first study to show DR-induced amelioration 
of iron dyshomeostasis in the SN, a region known to be 
particularly vulnerable to disease, intimating a potential 
pivotal role for SN in development of the aging 
phenotype. Our results highlight iron chelation therapies 
as potential putative “anti-brain aging” interventions, 
which may also attenuate the risk of developing 
neurodegenerative diseases, particularly Parkinson’s 








































placed at  the end of  the graph; ### P < 0.001  for an effect of  treatment; αα, P < 0.01  for an age‐feeding  regimen
interaction. (B) Age‐related reductions  in ferritin‐immunopositive cell numbers  in the SN between 7 and 19 months
are ameliorated in DR mice compared to AL mice. [Solid black line indicates the outcome of two‐way ANOVA testing;
*** P < 0.001 for effect of age; no significant effect of DR or age‐feeding regimen  interaction. Dotted  line  indicates
post‐hoc testing at significance level ** P < 0.01.] Micrographs showing decreased ferritin‐positive cells in SN of (C) AL
compared to (D) DR mice at 19 months of age. Black arrows point to ferritin‐immunopositive cells. 



































In the STR, we observed a continual increase in R2* 
with aging, consistent with human studies [22, 38]. We 
show increased R2* was correlated with increased iron, 
at least up to 19 months of age. Maximum iron content 
was observed at 19 months in mice, consistent with 
similar observations in man [6] at corresponding ages 
[39].  Whilst human studies showed significant 
correlations of R2* to histochemical-detected iron [6], 
we show R2* correlations with direct semi-quantitative 
iron measurements, as well as within the same spatial 
region of the same sample. 
 
In the GP, rapid increases in R2* [22] and iron [6] 
during early life have been shown in humans, followed 
by a plateau at 30 - 40 years of age. No initial rapid 
increase in R2* or iron in the GP was observed in our 
study. However, Haacke et al., (2010) [38] did report 
similar findings to those reported here in humans of a 
comparable age range to mice in our study, i.e., with the 
youngest being young adults as opposed to children as 
in the Aquino et al., (2009) study [22]. Whilst full 



































sarily be expected, these results intimate a need for 
developmental aging to be distinguished from 
senescence, at least when considering changes in iron 
and relaxation rates. 
 
Our finding of increased R2* in the STR and GP 
between 19 - 27 months without concomitant increased 
accumulation of iron is noteworthy, although in the 
latter, there was a trend towards increased iron albeit 
significance was not reached. The increased R2* in the 
STR, alongside unchanged levels of iron, suggest iron is 
partitioning into different forms with aging.  Iron is 
often associated with ferritin but may also bind to 
hemosiderin and magnetite. Hemosiderin-iron is an 
aggregate that induces greater spin dephasing [40] and 
so has a greater effect on T2* (and thus R2*) than 
ferritin-iron, which acts mostly through T2 relaxation 
[40]. Iron associated with biogenic magnetite also has a 
higher magnetic moment than that stored in ferritin and 
better at enhancing T2 relaxation [41]. A shift in the 
proportion of iron to these more magnetically active 
forms in the STR could thus account for R2* increases, 
Figure 9.  (A) Dietary  restriction has no effect on age‐related  increases  in GFAP positive astrocytes. Solid
black line indicates the outcome of two‐way ANOVA testing; **** P < 0.0001 for effect of age; no significant
effect of DR or age‐feeding  regimen  interaction. Dotted  line  indicates post‐hoc  testing at  the significance
levels  **  P  <  0.01  and  ***  P  <  0.001. Micrographs  showing  no  difference  in  GFAP  positive  astrocytes
between (B) AL and (C) DR mice at 19 months. Black arrows point to GFAP‐immunopositive cells. 
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without concomitant increases in iron. One study has 
reported increased hemosiderin in the aged (>65 years 
of age) putamen, a sub-region of the STR [42].  
 
Aquino et al., (2009) showed age-related increases in 
SN R2* over the lifespan (1 – 80 years)  [22], similar to 
that reported here.  However, one post-mortem study 
showed the majority of iron accumulation occurred very 
early in life [43] and another, a more linear increase 
[44]. The apparently contradictory findings between 
these two human studies most likely arise from 
differences in sample age ranges, again highlighting the 
need to distinguish developmental from biological 
aging. The trajectory of iron accumulation in our study 
is consistent with that of Zecca et al., (2004) [44], who 
used a similar sample age range.  
 
Both R1 and R2 values in the basal ganglia exhibited an 
overall increase with age. Whilst both measures 
significantly correlated to iron as in human studies [45], 




































as previously reported [46, 47]. Interestingly, for R1 
and R2 particular, nonlinear regression analysis showed 
these relaxation times tended to plateau at higher iron 
concentrations, suggesting there is a saturation point for 
the influence of iron on these relaxation rates: this 
saturation effect was not readily observed for R2*. It 
was noted R2 remained a reliable predictor for changes 
in brain iron during senescence, with a greater influence 
of other tissue factors on R2 occurring up to 13 months 
of age (see below).  
 
R2 values were similar between 6 - 13 months in the GP 
and SN, with a significant decrease observed in the 
STR, despite iron accumulation, which would increase 
R2. Astrogliosis has been shown to increase T2 
(decrease R2) [48] potentially by enlarging the 
extracellular space and increasing interstitial fluid 
content [49-51]. Indeed, astrocytes are more reactive 
with aging [52] and the demonstrable increased 
astrogliosis shown in the STR here likely accounts for 






































of treatment; α, P < 0.05 for an age‐feeding regimen  interaction. Dotted  line  indicates post‐hoc testing at the
significance levels ** P < 0.01 and *** P < 0.001.] Micrographs showing higher numbers of Iba1‐positive cells in
(B) AL compared to (C) DR mice at 19 months. Black arrows point to Iba1‐immunopositive cells. 
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without a measurable decrease in STR volume.  The 
decreased R2 in the STR may also result from neuronal 
loss, although unlikely, given the lack of atrophy over 6 
– 19 months.  Alterations in cellular content and tissue 
structure clearly play a prevalent role on age-related 
change in R2, at least up to 13 months. This may 
potentially mask the influence of iron accumulation on 
R2 to this point and may also explain why studies with 
narrower age ranges have reported no age-related 
alterations in T2 [53, 54]. Of note, after 13 months, R2 
changes in all the basal ganglia regions mirrors R2*, 
demonstrating R2 is as suitable a proxy for iron content 
as R2* in advanced aging. 
 
Overall, the smallest effect of age was seen on R1 
relaxation rate, which we have shown to have the least, 
albeit significant, correlation to iron. The overall pattern 
of R1 change across the mouse lifespan reflects the 
increase in iron, but without the specificity of R2* or 
even R2.  
 
DR has previously been demonstrated as a robust “anti-
brain aging” intervention [27]. We have highlighted the 
SN as a potentially crucial region of deleterious iron 
accumulation in aging, especially due to its high 
neuronal vulnerability [11]. In this context, our most 
pertinent finding is that DR ameliorates in vivo age-
related R2 increases in the SN alongside inhibited iron-
induced up-regulation of ferritin. Other studies have 
also shown DR-amelioration of increases in T2 with 
aging [16], but not in the serial manner here or with 
corroborating ferritin IHC measurements.  The demons-
trable strength of ex vivo R2 to predict elevations in iron 
(particularly during senescence) in the current 
investigation lends credence that the amelioration of 
age-related increases in in vivo R2 following 12 months 
pertain to DR-attenuation of iron accumulation.  
 
Under normal homeostatic control, increased cellular 
iron induces expression of ferritin to increase iron-
storage capacity [55]. Indeed, increased iron in the GP 
throughout aging, alongside increased ferritin-positive 
cells shown here, has been documented previously [56]. 
In the STR, higher ferritin-immunopositive cell 
numbers preceded iron accumulation over 2 – 6 months, 
but did not continue to increase over 6 – 19 months, 
despite increased iron, suggesting that ferritin is only 
partially loaded with iron in the STR of younger brains. 
Ferritin can store up to 4500 atoms of iron and in 
peripheral tissues at least, ferritin remains only partially 
saturated with iron [57]. Increased ferritin-immuno-
positive cell numbers at 27 months compared to 6 
suggest that existing ferritin levels are insufficient to 
accommodate the increasing iron levels. Studies in 
rodents and man have also shown increased ferritin in 
the STR with aging [55, 56], with one rat study showing 
a similar pattern of iron and ferritin change in the STR 
as we have reported here [55].  
 
Unexpectedly, the increased iron levels in the SN over 6 
and 19 months were accompanied by a decrease, rather 
than an increase, in ferritin-immunopositive cells, 
suggesting iron dysregulation. The impaired iron 
handling/storage with aging in the SN may predispose 
this region to oxidative damage and subsequent 
neurodegeneration, and contribute to the select neuronal 
vulnerability of this region [11]. Rather than being 
sequestered in ferritin, the excess iron may be 
sequestered in neuromelanin (NM), given the 
prevalence of NM-containing dopaminergic neurons in 
the SN [58]. Indeed, NM is known to associate with 
iron and shown to increase with aging [43, 44]. 
Furthermore, Zecca et al., (2004) reported impaired 
ferritin expression in aged SN neurons in man alongside 
significantly large amounts of NM-bound iron. NM may 
protect neurons against toxic quinone and semi-
quinone, by-products of dopamine metabolism [59], 
with the SN having the highest dopaminergic neuronal 
content. However, at high iron concentrations, NM 
becomes saturated, leading to a potentially pro-oxidant 
environment [60, 61] and indeed high levels of NM, 
have been associated with SN neurodegeneration in 
middle-aged mice [62]. Whether excess iron is indeed 
sequestered by NM in aging and if so, whether the iron 
level reported here is sufficient to saturate NM in the 
SN, warrant future investigation. 
 
Iron mishandling in the SN may have prevalent effects 
throughout the brain as SN dopaminergic projections 
modulate striatal neurons [63], affecting sensorimotor 
learning and memory [64]. Further, decreases in nigral 
neurons with aging [65] may precipitate impaired 
dopaminergic innervation and consequent behavioral 
abnormalities [66]. Indeed, studies have shown D1 and 
D2 dopamine receptor losses in the STR with aging [67], 
as well as a reduced ligand binding [68].  Others have 
shown that the caudal and lateral STR, receiving 
afferent input from the A9 SN neurons, exhibit 
decreases in dopamine content [69]. In light of this, iron 
dyshomeostasis in the SN demonstrated here, may play 
a prevalent and crucial role in stimulating oxidative 
damage of the melanized dopaminergic neurons, 
contributing to their vulnerability and explaining the 
extrapyramidal symptoms of the aging brain. 
 
In PD, death of dopaminergic neurons in the SN pars 
compacta decreases dopamine levels in the prefrontal 
cortex and STR [70], leading to cognitive and motor 
dysfunction [71]. A feature of PD is the greater iron 
accumulation in the SN than in aging [5, 72] and similar 
to the current investigation, iron-induced ferritin 
expression is also inhibited  [73]. Additionally, in-
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creased redox activity in NM aggregates of melanized 
neurons has been observed in PD, with NM-positive 
staining shown to positively correlate with ferric iron 
content [61]. The potential role of NM in PD 
pathophysiology poses an interesting question regarding 
its role in iron sequestration with respect to normal 
aging, given the similarity in iron alterations of our 
study to that reported previously in PD [73]. 
 
We have shown age-related increases in GFAP-positive 
astrocytes in the basal ganglia regions, consistent with 
previous studies [74, 75].  The expanded end feet of 
astrocytes encompass the brain capillary endothelial 
cells (BCECs) [76] and facilitate the transport of 
various metabolites and metals, including iron, into the 
neuropil [76]. Astrocytes not only take up iron as 
transferrin-bound iron, they can also import iron via the 
divalent metal transporter 1 (DMT1), which are 
expressed at astrocytic endfeet [77]. We show that the 
time-course of the increases in GFAP-immunopositive 
cells during aging was similar to that for iron 
accumulation in the STR and the SN, and may arise 
from the known uptake and storage of iron in astrocytes 
[75]. Indeed, one third to three quarters of the iron in 
the brain is stored in glial cells [78]. The increases in 
iron in the STR, possibly from increased astrocytic 
uptake and storage, is associated with a corresponding 
increase in ferritin-immunopositive cells, suggesting the 
increased iron is stored with ferritin. However, in the 
SN, the increases in both astrocytes and iron levels are 
not concomitant with an increase in ferritin-positive 
cells. As mentioned before, the excess iron does not 
appear to be bound by ferritin and may become 
dependent on NM for non-toxic storage.  
 
In the GP, however, astrocyte levels were comparable 
except between 2 and 27 months, despite increased iron 
during this time. Iron can still be accumulating in 
astrocytes in the GP, without a corresponding increase 
in astrocytes numbers, as the astrocytes numbers in the 
GP at 2 months are relatively high compared to those in 
the STR, and appear to be sufficient to accommodate 
the increase in iron.  
 
A pro-inflammatory state has been demonstrated in 
aging, with increases in glial cell number [79] and an 
activated, dystrophic microglial phenotype previously 
reported. Stereotactic injections of lipopolysaccharide in 
the STR have been shown to increase microglial 
activation, ferritin expression and total nigral iron 
content in aged rats [80], with activated microglia 
shown to increase iron uptake and decrease export [81]. 
Thus, the microgliosis observed with aging in the three 
basal ganglia regions may, at least in part, explain the 
iron accumulation in these areas. Further, microgliosis 
in the STR was less pronounced and correlated with 
lower levels of iron accumulation.  Increased microglial 
iron uptake may induce pro-inflammatory cytokine 
release and neurodegeneration [82, 83]. Activated 
microglia produce superoxide, which is capable of 
stimulating iron release from ferritin [84], leading to 
increased labile iron, enhancing pro-oxidative capacity 
that is central to neuroinflammatory and neuro-
degenerative processes in aging. Indeed, Hayashi et al.,  
(2008), highlighted microglia as a major source of 
oxidation products in the aged mouse brain [85].  
 
The decreased ferritin storage potential of iron in the 
SN reported in the current investigation alongside 
astrogliosis, combined with the tendency for aged 
microglia to become dystrophic and render iron more 
redox-active [84, 86], cements the SN as a particularly 
vulnerable region in aging. The interplay between iron 
accumulation and glial cell populations requires further 
exploration to elucidate the full extent to which this 
region contributes to the aged phenotype. 
 
Whether microgliosis precedes and induces the 
increases in iron uptake and/or whether iron 
accumulation occurs initially and contributes to 
microglial activation/dystrophy remains to be seen. In 
regard to the latter, the role of microglia in long term 
storage of iron has previously been noted, with storage 
of iron potentially increasing microglial dystrophy [86]. 
Reduced iron accumulation, as suggested by  T2, has 
been associated with improved motor performance [16].  
Iron may have a critical role in the age-related increase 
and activation of microglia in aging. In light of this, the 
demonstrable reduction of microglia in the SN by DR, 
combined with apparent amelioration of iron 
dyshomeostasis, highlights that restoration of iron 
homeostasis could be a key facet of the beneficial 
effects of DR [35]. Determining if a causal relationship 
exists between the apparent restoration of iron 
homeostasis and reduced microglia, or if the reverse is 
true, could help prove the efficacy of iron chelation 
therapies or anti-inflammatory treatments, respectively. 
However, combining the two therapeutic strategies may 
prove to be synergistic.  Indeed, interactions of 
inflammatory signaling molecules and iron in PD have 
been discussed in Pretorius et al., (2014) [87] and 
suggested to enhance eryptosis in the periphery.  
Whether the effects of DR in the SN shown here can 
incite beneficial changes in other regions known to be 
affected during aging, such as the STR that receives 
significant dopaminergic innervation from the SN, 
remains to be seen.    
 
In addition, the lack of an astrocytic reaction, 
concomitant with iron dyshomestasis and microgliosis 
certainly supports the idea that microglia rather than 
astrocytes, plays a more dominant role in the handling 
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of iron in the SN. The lack of effect of DR on astrocytes 
in the SN is interesting given previous reports of DR 
reducing age-related increases GFAP, albeit not 
specifically in the SN [88].  
 
The integration of in vivo and in vitro iron measures 
alongside ferritin and glial immunohistochemistry in the 
aged mouse brain provides formative insight into the 
regulation of brain iron in aging, but also the 
importance of iron dyshomeostasis and neuro-
inflammation on brain aging and as possible targets for 
novel interventions. Further, we reveal the particular 
vulnerability of the SN to iron dyshomeostasis in aging, 
potentially mediating/resulting from age-related 
inflammation and contributing to the susceptibility of 
this brain area to neurodegenerative diseases, especially 
PD. In this context, DR, and in the future DR analogues, 
may serve as putative interventions against such 






All experimental procedures performed on mice were in 
compliance with the local ethical review panel of 
King’s College London and the U.K. Home Office 
Animals Scientific Procedures Act 1986.  
 
Animals and Treatment  
 
Study 1:  Ex vivo characterization of the aging 
mouse brain 
 
Male C57BL/6J mouse brains were obtained from 
Shared Aging Research Models, (ShARM, Sheffield, 
UK). Mice were culled at 2 (n = 11), 6 (n = 8), 13 (n = 
11), 19 (n = 11) and 27 months (n = 8) of age by rising 
CO2 inhalation (different numbers of mice were 
included at each age, depending on tissue availability.).  
Ages of mice chosen for study were equivalent to 
different stages of adulthood from just post-
adolescence, adult, midlife, elderly and the very elderly. 
The heads were removed and fixed in 4% paraformal-
dehyde (1 week) and stored in phosphate-buffered 
saline (PBS, 4°C) with 0.05% sodium azide prior to 
MRI, SRXRF and immunohistochemistry (see below).  
 
Study 2:  DR-induced attenuation of age-related 
brain changes 
 
Animals were maintained under standard laboratory 
conditions (room temperature automatically maintained 
at 21°C ± 1°C; 12h light:dark cycle). Mouse cages were 
provided with wood shavings and shredded paper 
bedding for enrichment.  Body weights and food intake 
data were recorded weekly. 
 
Male C57BL/6J mice (n = 24, aged 7 months old; 
Harlan, UK), were singly housed and acclimatized for 7 
days before allocation into two groups of 12. Following 
in vivo baseline MRI (see below), one group was fed ad 
libitum (AL), while the other, underwent an intermittent 
fasting regimen involving fasting on alternate days from 
17:30 – 11:00 h.  Mice were scanned again in vivo at 9, 
12, 15 and 19 months of age (see section on in vivo 
MRI below). After MRI at 19 months, mice underwent 
transcardial perfusion with heparinized (50 IU/ml) 
saline to flush out blood from the vasculature before 
perfusion-fixation with 4% paraformaldehyde under 
terminal anaesthesia. Heads were decapitated and fixed 
for a further week in 4% paraformaldehyde before 
storage in 0.05 % azide-supplemented PBS at 4oC until 




Ex vivo MRI: Brains within the skull were prepared for 
MRI (see below) by removal of, the skin, muscle, lower 
jaw, tongue, nasal bones and zygomatic arches, and 
embedded in perfluoropolyether (Galden™, 
Performance Fluids, UK, Solvoy Solexis) to minimize 
susceptibility and prevent tissue dehydration during 
scanning. Care was taken to avoid air bubbles. MRI was 
performed using a quadrature volume radiofrequency 
coil (33 mm internal diameter; Rapid Biomedical, 
Rimpar, Germany) on a 7T horizontal bore MRI 
scanner (Agilent Technologies Inc, Walnut Creek, CA, 
USA). 
 
T1 relaxometry was achieved with a 2D spin-echo (SE) 
sequence with repetition times (TR) of 670, 800, 1000, 
1200, 2000 and 4000 ms; echo time (TE), 11 ms and 2 
averages. A 2D multi-echo, SE sequence was run with 
TE, 11.6, 34.8, 58.0, 81.2, 104.4, 127.6, 150.8 and 
174.0 ms; TR, 7600 ms and 4 averages, to measure T2. 
To account for stimulated echoes only data from the 
odd TEs were included in the T2 fitting (see below). 
T2* was assessed with a 2D multi-echo gradient echo 
sequence with five echoes and TE, 2.5, 8.5, 14.5, 20.5, 
26.5 ms; TR, 2000 ms and 10 averages, flip angle 90°. 
Contiguous coronal slices (40, 0.5 mm thick) were 
recorded with field of view (FOV), 30 × 30 mm and 
matrix size, 256 × 256 for all relaxometry. 
 
In vivo MRI: T2 relaxometry was performed as for 
brain samples at baseline (7 months), 9, 12, 15 and 19 
months but with TE (10.6, 21.3, 31.9, 42.6, 53.2, 63.9, 
74.5, 85.2, 95.8, 106.5, 117.1, 127.8, 138.4, 149.1, 
159.7 and 170.4 ms) and TR, 5217 ms; 2 averages and 
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30 contiguous coronal slices at 0.5 mm thick; FOV, 20 
× 20 mm and matrix size = 128 × 128. 
 
MRI image analysis 
 
T1, T2 and T2* maps were generated by pixel-by-pixel 
non-linear fitting to equations: y = A (1-exp(-TR/T1)), y = 
B(exp(-TE/T2)) and y = C(exp(-TE/T2*)), respectively (A, B 
and C are constants that represents signal components 
that were unchanged in each experiment) in JIM 5.0 
(Xinapse Systems, Alwincle, UK). R1, R2 and R2* 
maps (R2 only for study 2) were then calculated by 
performing the reciprocal function for each maps. 
Structural images were produced by summing the 
shortest 8 echoes of the T2 relaxometry data using 
proprietary scanner software and these images used for 
manual tracing of the striatum for volumetric 
assessment. 
 
Regions of interest (ROIs) were manually drawn in the 
STR, GP and SN on the high quality structural images 
(guidelines listed in supplemental Table 2, according to 
a standard mouse brain atlas [89]) using ImageJ 
(National Institute of Health, Maryland, USA), and then 
placed onto each of the directly registered relaxation 
rate maps.  Note the structural images were produced 
from the T2 relaxometry data (see above).  As all 
relaxometry data was collected in the same scan session 
without moving the brains, accurate registration 
between the structural image and all relaxometry maps 
was possible.  Relaxation rates for each anatomical ROI 
were obtained and averaged for each age before 
statistical testing in Prism v5 (GraphPad, SD, USA). 
For volume analysis, striatal ROIs were delineated as 
previously described [90].  
 
Cryoprotection and tissue sectioning 
  
Following MRI acquisition, brains from 5 mice per 
group from both studies (not including 13 month old 
mice from study 1 as these brains were obtained 
sometime after synchrotron access) were cryoprotected 
in 30% sucrose (PBS, 0.05% sodium azide).  
Subsequently, cryosectioning was performed coronally 
to produce 40 μm thick frozen sections that were 
mounted onto 4 μm thick Ultralene film (Spex Sample-
Prep, NJ, USA) secured to a customized holder for 
SRXRF.  Cryosections sections of 20 μm thick were 
also obtained and mounted onto Superfrost plus 
microscope slides for IHC. Not all the brains at the 
various ages that had previously undergone MRI were 
analyzed by SRXRF as synchrotron access is very 
limited.  Likewise, only sufficient numbers of brains at 
the various ages needed for statistical testing were 
analyzed by IHC. 
SRXRF elemental mapping and analysis 
 
SRXRF of whole/right hemisphere of brain tissue 
sections was performed on the I18 beamline at the 
Diamond Light Source synchrotron radiation facility 
(Didcot, UK). The beam energy was tuned to 11 keV 
and focused to 100 × 100 μm (determining resolution) 
and the brains scanned in a raster manner. The brain 
samples were mounted at a 45° angle with respect to the 
incoming X-ray beam and the detector to minimize 
scatter contribution. The raw data consist of full energy 
dispersive spectra for each sample point exposed to the 
beam. The spectra were subsequently fitted and the net 
peak areas of the characteristic Kα and Kβ peaks of iron 
were evaluated using PyMca [91]. Quantification was 
performed by measuring a reference metal film (AXO, 
Dresden, GmbH), which allows estimation of the 
photon flux on the samples. SRXRF elemental maps of 
pixel-by-pixel iron concentrations (mg/kg wet weight) 
were manually aligned to the corresponding relaxation 
rate maps using ImageJ.  Thus, ROIs, similar to that for 
the relaxation maps, could be placed at the equivalent 





Standard DAB IHC was performed. Endogenous 
peroxidase activity was blocked by incubation with 1% 
H2O2 in Tris- buffered saline, pH 7.4 containing 0.2% 
Triton X-100 (TBS+; 30 mins, RT). After 2 X 5 mins 
washes in TBS+, non-specific binding was blocked 
using 10% skimmed milk power (SMP) in TBS+ (2 h, 
RT). Sections were then incubated with either rabbit 
anti-ferritin antibody (F6136; Sigma-Aldrich, Poole, 
Dorset, UK), rabbit polyclonal anti-Iba-1 antibody (019-
19741; Wako Pure Chemical Industries, Richmond, 
VA), rabbit polyclonal anti-GFAP antibody (DAKO, 
High Wycombe, UK) in 5% SMP in TBS+ (overnight, 
4°C). After washes in TBS+, slides were incubated with 
secondary biotinylated anti-rabbit IgG (1:200, DAKO, 
High Wycombe, UK) in 5% SMP in TBS+ (2 h, RT). 
Avidin-biotin binding was then performed using the 
ELITE ABC kit (Vector, Peterborough, UK) for ferritin 
and Iba1 immunohistochemical protocols, respectively, 
prior to the chromogenic reaction using the Impact 
DAB peroxidase kit (Vector, Peterborough, UK). Slides 
were subsequently dehydrated in ascending grades of 
ethanol, cleared in xylene and mounted using DPX 
(Sigma-Aldrich, St Louis, MO, USA).  
 
Histological image analysis 
  
Sections were scanned on a LEICA SCN400F scanner 
(University College London, London) to produce 20× 
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magnification digital images from 4 sections per mouse 
in the STR (Bregma +1.10 to 0.50 mm), GP (Bregma -
0.22 to -0.70mm) and SN (Bregma -3.08 to -3.64 mm) 
from the right hemisphere for each section. Depending 
on the region, 2 – 4 optical fields were taken, each 
comprising a 628.0 × 278.5 µm2 area.  Ferritin, GFAP 
or iba1 immunopositive cells in each optical field were 
manually counted using the cell counter plugin of 
ImageJ and expressed as number of immunopositive 




Spearman’s rank-order correlation and nonlinear 
regression analysis was performed to assess the strength 
of the association between R1, R2 and R2* with 
SRXRF measured elemental iron in all basal ganglia 
regions. Statistical testing of correlations was performed 
using cocor [92].   
 
One way analysis of variance (ANOVA) with post-hoc 
Tukey’s correction (Prism v5, GraphPad, San Diego, 
CA, USA) was used to test for differences in individual 
relaxation rates, iron, ferritin, Iba1 and GFAP-
immunopositive cells and normalized STR volume with 
aging (study 1). A two-way ANOVA with repeated 
measures and post-hoc Sidak’s multiple comparisons 
test was used for testing differences in in vivo R2 with 
aging and feeding regimen (study 2). Two-way 
ANOVA was also used to test for differences in ferritin, 
Iba1 and GFAP-immunopositive cell numbers between 
AL and DR mice in study 2. 
 
All values quoted are mean ± standard error of mean 
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Measurement Brain region 
 
Age 
2 month 6 month 13 month 19 month 27 month 
R1 relaxation rate Striatum 0.67 ± 0.01 0.70 ± 0.01 0.69 ± 0.02 0.69 ± 0.01 0.73 ± 0.01 
Globus Pallidus 0.70 ± 0.01 0.75 ± 0.01 0.76 ± 0.01 0.78 ± 0.01 0.82 ± 0.01 
Substantia Nigra 0.65 ± 0.01 0.69 ± 0.01 0.69 ± 0.01 0.71 ± 0.01 0.72 ± 0.01 
R2 relaxation rate Striatum 19.3 ± 0.18 20.5 ± 0.20 19.8 ± 0.12 20.8 ± 0.13 21.2 ± 0.17 
Globus Pallidus 20.7 ± 0.22 22.5 ± 0.21 22.6 ± 0.16 24.9 ± 0.23 24.8 ± 0.55 
Substantia Nigra 17.3 ± 0.42 20.1 ± 0.33 19.8 ± 0.33 21.7 ± 0.37 22.0 ± 0.80 
R2* relaxation rate Striatum 25.4 ± 0.28 26.7 ± 0.62 28.0 ± 0.18 29.6 ± 0.32 32.3 ± 0.96 
Globus Pallidus 29.5 ± 0.43 32.1 ± 0.34 38.6 ± 0.53 44.8 ± 0.52 50.2 ± 1.41 
Substantia Nigra 24.7 ± 0.67 31.4 ± 1.01 32.5 ± 1.10 37.0 ± 0.82 38.8 ± 1.34 
Synchrotron radiation-based  
X-ray Fluorescence measured 
iron (wet weight mg/kg) 
Striatum 19.3 ± 0.78 23.2 ± 2.31 Not measured 35.2 ± 1.76 36.9 ± 1.85 
Globus Pallidus 23.1 ± 1.31 27.5 ± 1.28 Not measured 71.5 ± 7.63 94.1 ± 8.86 
Substantia Nigra 20.0 ± 1.44 29.7 ± 1.96 Not measured 60.2 ± 8.43 66.9 ± 13.2 
Ferritin  
(10-4 cell counts/µm2) 
Striatum 3.4 ± 0.1 4.1 ± 0.1 Not measured 5.8 ± 0.2 5.9 ± 0.2 
Globus Pallidus 4.8 ± 0.3 6.0 ± 0.4 Not measured 8.8 ± 0.3 9.5 ± 0.1 
Substantia Nigra 4.9 ± 0.2 5.6 ± 0.3 Not measured 4.2 ± 0.3 4.3 ± 0.1 
GFAP   
(10-5 cell counts/µm2) 
Striatum 5.0 ± 0.7 8.0 ± 0.6 Not measured      17.5 ± 0.3      31.2 ± 0.5 
Globus Pallidus 54.0 ± 13.0 66.8 ± 6.91 Not measured 68.1 ± 10.3    104.7 ± 12.0 
Substantia Nigra       49.3 ± 2.0        41.3 ± 2.8 Not measured      55.6 ± 3.0       53.8 ± 2.8 
Iba1  
(10-5cell counts/µm2) 
Striatum       18.2 ± 2.2        19.3 ± 0.5 Not measured      22.0 ± 0.6       24.9 ± 2.0 
Globus Pallidus       30. 7 ± 0.6        28.3 ± 1.3 Not measured      33.1 ± 2.7 38.5 ± 0.7 
Substantia Nigra        30.0 ± 1.3        25.1 ± 1.9 Not measured      31.1 ± 1.7 35.0 ± 0.7 
Normalized volume (mm3) Striatum 0.0429 ± 0.0005 0.0406 ± 0.0006 0.0387 ± 0.0010 0.0383 ± 0.0003 0.0376 ± 0.0008 
Supplemental Table 2. Guidelines for delineation of basal ganglia ROIs for MRI and SR‐XRF data analysis. 
 
Brain region Approximate bregma (mm) Description 
Striatum +0.62 
Elliptical ROI placed under the 
corpus callosum close to, but 
ensuring not in the lateral ventricles 
Globus Pallidus -0.34/-0.46 
Elliptical ROI, with the right edge 
lined up with the lateral ventricles 
and left edge delineated by the 
contrast difference between the 
striatum and globus pallidus. Height 
defined by the space between the 3rd 
dorsal ventricle and the 3rd ventricle. 
Substantia Nigra -3.28 
Small elliptical ROI placed 
alongside the visible cerebral 
peduncle at the base of the ventral 
hippocampus. 
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Supplemental Figure 1. Normalized striatal volumes decrease steadily
with advancing age. Significance  level at ***, P < 0.001, compared to 2
month and #, P < 0.05 compared to 6 months, respectively. 
